ALAnnie-Claude Labbé

Annie-Claude Labbé

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Annie-Claude Labbé has a total of 171 co-authors. Here are the top co-authors by number of shared publications:

  • Christian Lavallée

    Department of Microbiology, Infectious Diseases, and Immunology, Université de Montréal

    4 shared publications
  • Jeannot Dumaresq

    Département de microbiologie-infectiologie et d'immunologie, Faculté de Médecine, Université Laval, Québec, Québec, Canada

    4 shared publications
  • Judith Fafard

    Department of Microbiology, Infectious Diseases, and Immunology, Université de Montréal

    4 shared publications
  • François Coutlée

    Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal , Montréal, Quebec

    3 shared publications
  • Mariève Jacob‐Wagner

    Département de microbiologie et d'infectiologie du centre hospitalier universitaire (CHU) de Québec—Université Laval Québec Québec Canada

    3 shared publications
  • Simon Lévesque

    Division of Infectious Diseases and Microbiology, Centre Hospitalier Universitaire de Sherbrooke, CIUSSS de l’Estrie

    3 shared publications

Latest Publications

  • Open Access

    Diagnosis of chlamydial and gonococcal conjunctivitis: performance evaluation of a nucleic acid amplification test

    by Olivier Bédard, Émilie Vallières, Julie Vadboncoeur, Patrick Hamel, Christian Lavallée, Brigitte Lefebvre, Judith Fafard, Simon Lévesque, Mariam Ag Bazet, Claude Fortin, et al.

    No regulatory agency-approved nucleic acid amplification tests (NAATs) exist for detecting Chlamydia trachomatis (CT) or Neisseria gonorrhoeae (NG) in conjunctival samples, necessitating validation, including performance analysis. This is challenging due to case rarity and the absence of a gold standard. This retrospective case series evaluated the performance of the Roche cobas CT/NG NAAT on conjunctival samples using microbiological and clinical data. Clinical records of patients with positive CT/NG NAAT conjunctival samples processed in our laboratory between 2013 and 2023 were reviewed, along with matched negative controls. Positive results were confirmed using a stepwise algorithm: (i) positive NG culture (NG only); (ii) confirmatory CT/NG NAAT performed at the Laboratoire de santé publique du Québec (LSPQ); (iii) CT/NG NAAT from other anatomical sites; or (iv) clinical presentation compatible with CT/NG conjunctivitis. Negative controls were confirmed based on clinical information. Sixty-five positive conjunctival samples were included (53 CT-positive, 12 NG-positive). Of the 53 CT-positive samples, 52 were confirmed (21 by LSPQ testing, five by a concomitant genital sample, and 26 by a compatible presentation). Of 53 CT-negative controls, 45 were clinically confirmed as true negatives. Among the 12 NG-positive samples, 11 were confirmed (seven by culture, four by LSPQ testing). Of 12 NG-negative controls, 11 were clinically confirmed. Sensitivity and specificity were 87% and 98% for CT, and both were 92% for NG. Given sufficient data, the Roche cobas CT NAAT assay on conjunctival samples does not require confirmatory testing. However, confirmation of NG-positive results should continue until more data are available. IMPORTANCE: Chlamydia trachomatis (CT) conjunctivitis has been increasingly observed in adults and neonates. If untreated, it can cause local complications and, in adults, contribute to ongoing transmission. Neisseria gonorrhoeae (NG) conjunctivitis is rarer, but its hyperacute presentation can lead to severe outcomes, such as orbital cellulitis or globe rupture. Conventional diagnostic methods for CT are either unavailable or highly resource-consuming, and NG culture lacks sensitivity, underscoring the need for rapid and reliable diagnostic methods. Nucleic acid amplification tests (NAATs) are considered the gold standard for detecting CT and NG in urogenital, pharyngeal, and rectal sites, due to their high sensitivity and specificity. Despite widespread use on conjunctival specimens, no NAAT is approved by regulatory agencies. Evaluation of the Roche cobas CT/NG assay is crucial to establish its performance on conjunctival specimens and to provide clinicians with accurate, timely diagnostic results.

  • Open Access

    Risk factors of multidrug-resistant gonococcal infections: an analysis of data from the sentinel surveillance network- Québec, Canada, 2017–2019

    by Jean-Pierre Gnimatin, Annick Trudelle, Annie-Claude Labbé, Karine Blouin

    The emergence of antimicrobial resistance (AMR) in Neisseria gonorrhoeae is a worrying global phenomenon, with major implications for public health. This study, a cross-sectional analysis of an open cohort, explored the risk factors associated with multidrug-resistant (MDR) gonococcal infections in the province of Québec, Canada, using data from the sentinel surveillance network from 2017 to 2019. The data comprised sociodemographic, epidemiological, and clinical information, collected through self-administered questionnaires, direct case interviews and chart reviews coupled with laboratory AMR data for five antibiotics: azithromycin, tetracycline, ciprofloxacin, cefixime, and ceftriaxone. Missing data were handled using multiple imputation with chain equations (MICE); generalized estimating equations (GEE) were used to assess correlates of MDR. The analysis included 714 participants with a total of 775 cases. We observed very frequent resistance to ciprofloxacin (74.3%), while resistance to tetracycline and azithromycin was 19.9% and 21.3%, respectively. MDR was found in 12.5% of cases. Multivariate analysis indicated that having five or more sexual partners in the past two months (aPR=1.61, 95%CI: 1.07-2.41) was associated with MDR. In conclusion, our results show an association between the number of sexual partners and MDR, supporting the hypothesis that resistance can develop more rapidly in dense sexual networks. It is crucial to address the issue of circulating resistant strains through ongoing surveillance, research, and targeted interventions to manage and contain them before they become widespread.

  • Open Access

    Armstrong strain lymphocytic choriomeningitis virus infection after accidental laboratory exposure

    by Laurence Caron, Jean-Sébastien Delisle, James E Strong, Yvon Deschambault, Félix Lombard-Vadnais, Annie-Claude Labbé, Sylvie Lesage

    Background: Lymphocytic choriomeningitis virus (LCMV) is a human pathogen naturally present in wild rodents. In addition, LCMV is routinely used in immunology research as a model of viral infection in mice. The Armstrong common laboratory strain and the Clone-13 variant induce acute and chronic infections in mice, respectively. The frequent use of this virus in laboratory settings is associated with a risk of human infection for laboratory personnel. In contrast to LCMV Clone-13, few human laboratory infections with LCMV Armstrong have been reported, leading to a poor understanding of symptoms related to infection with this specific LCMV strain. Case presentation: A researcher accidentally infected herself percutaneously with LCMV Armstrong. Symptoms including headaches, dizziness, eye pain and nausea appeared seven days post-exposure and lasted ten days. LCMV-IgM antibodies were detected at 28 days post-infection and IgG seroconversion was observed later. Complete recovery was confirmed three months post exposure. Conclusions: Research involving live viruses comes with the risk of infection for research personnel. This case is the first reported accidental human infection with LCMV Armstrong. The symptoms differed from reported infections with LCMV Clone-13, by the absence of fever and vomiting, and presence of leg numbness. This report will therefore help clinicians and public health authorities to recognize the symptoms associated with LCMV Armstrong infections and to offer appropriate counselling to individuals who accidentally expose themselves.


  • Open Access

    Condylomes plats vulvaires comme premières manifestations de la syphilis

    by Justine Robillard, Chantal Rivard, Annie-Claude Labbé

  • Open Access

    Vulvar condyloma lata as a first presentation of syphilis

    by Justine Robillard, Chantal Rivard, Annie-Claude Labbé


  • Open Access

    Clinical performance of SARS-CoV-2 detection on the cobas Liat using water gargle samples

    by Maxime Veillette, Francine Tourangeau, Judith Fafard, Jeannot Dumaresq, Annie-Claude Labbé


  • Association of Obstructive Sleep Apnea with Mechanical Ventilation in Hospitalized SARS-CoV-2 Patients

    by Martel- Pelletier, A. Bartholi, S. Benchekroun, E. Melancon, H.T. Wang, A.-C. Labbé, C. Lavallée, X. Marchand-Sénécal, M. Brosseau

  • Evaluation of water gargle samples for SARS‐CoV‐2 detection using Abbott ID NOW COVID‐19 assay

    by Simon Lévesque, Stéphanie Beauchemin, Maud Vallée, Jean Longtin, Mariève Jacob‐Wagner, Jeannot Dumaresq, Carlos Dulcey, Annie‐Claude Labbé

    The Abbott ID NOW™ COVID‐19 assay has been shown as a reliable and sensitive alternative to reverse transcription‐polymerase chain reaction (RT‐PCR) testing from nasopharyngeal or nasal samples in symptomatic patients. Water gargle is an acceptable noninvasive alternative specimen for severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) detection by RT‐PCR. The objective of this study was to evaluate the performance of water gargle samples for the detection of SARS‐CoV‐2 using the ID NOW. Residual gargle samples were randomly selected among positive standard of care (SOC)‐nucleic acid amplification test (NAAT) samples. For testing on ID NOW, the manufacturer's instructions were followed, except for the specimen addition step: 500 µl of the gargle specimen was added to the blue sample receiver with a pipette and gently mixed. Among the 202 positive samples by SOC‐NAAT, 185 were positive by ID NOW (positive percent agreement [PPA]) = 91.6% (95% confidence interval [CI]: 86.9−95.0). For the 17 discordant samples, cycle threshold (Ct) values were all ≥31.0. The PPA was significantly lower among asymptomatic patients (84.4%; 95% CI: 73.2−92.3) versus symptomatic patients (95.2%; 95% CI: 89.8−98.2). The performance of the ID NOW for the detection of SARS‐CoV‐2 infection on gargle samples is excellent when Ct values are <31.0 and for patients that have COVID‐19 compatible symptoms.


  • Open Access

    Outcomes of hospitalized COVID-19 patients in Canada: impact of ethnicity, migration status and country of birth

    by Ana Maria Passos-Castilho, Annie-Claude Labbé, Sapha Barkati, Me-Linh Luong, Olina Dagher, Noémie Maynard, Marc-Antoine Tutt-Guérette, James Kierans, Cecile Rousseau, Andrea Benedetti, et al.

    Ethnoracial groups in high-income countries have a 2-fold higher risk of SARS-CoV-2 infection, associated hospitalizations, and mortality than Whites. Migrants are an ethnoracial subset that may have worse COVID-19 outcomes due to additional barriers accessing care, but there are limited data on in-hospital outcomes. We aimed to disaggregate and compare COVID-19 associated hospital outcomes by ethnicity, immigrant status and region of birth. Adults with community-acquired SARS-CoV-2 infection, hospitalized March 1–June 30, 2020, at four hospitals in Montréal, Quebec, Canada, were included. Age, sex, socioeconomic status, comorbidities, migration status, region of birth, self-identified ethnicity [White, Black, Asian, Latino, Middle East/North African], intensive care unit (ICU) admissions and mortality were collected. Adjusted hazard ratios (aHR) for ICU admission and mortality by immigrant status, ethnicity and region of birth adjusted for age, sex, socioeconomic status and comorbidities were estimated using Fine and Gray competing risk models. Of 1104 patients (median [IQR] age, 63.0 [51.0–76.0] years; 56% males), 57% were immigrants and 54% were White. Immigrants were slightly younger (62 vs 65 years; p = 0.050), had fewer comorbidities (1.0 vs 1.2; p < 0.001), similar crude ICU admissions rates (33.0% vs 28.2%) and lower mortality (13.3% vs 17.6%; p < 0.001) than Canadian-born. In adjusted models, Blacks (aHR 1.39, 95% confidence interval 1.05–1.83) and Asians (1.64, 1.15–2.34) were at higher risk of ICU admission than Whites, but there was significant heterogeneity within ethnic groups. Asians from Eastern Asia/Pacific (2.15, 1.42–3.24) but not Southern Asia (0.97, 0.49–1.93) and Caribbean Blacks (1.39, 1.02–1.89) but not SSA Blacks (1.37, 0.86–2.18) had a higher risk of ICU admission. Blacks had a higher risk of mortality (aHR 1.56, p = 0.049). Data disaggregated by region of birth identified subgroups of immigrants at increased risk of COVID-19 ICU admission, providing more actionable data for health policymakers to address health inequities.


  • Open Access

    Monocyte Gene and Molecular Expression Profiles Suggest Distinct Effector and Regulatory Functions in Beninese HIV Highly Exposed Seronegative Female Commercial Sex Workers

    by Laurence Blondin-Ladrie, Lyvia Fourcade, Alessandro Modica, Matheus Aranguren, Nicolas de Montigny, Annie-Claude Labbé, Michel Alary, Fernand Guédou, Johanne Poudrier, Michel Roger

    We have previously reported that the female genital tract (FGT) of Beninese HIV highly-exposed seronegative (HESN) commercial sex workers (CSWs), presented elevated frequencies of a myeloid HLA-DR+CD14+CD11c+ population presenting “tolerogenic” monocyte derived dendritic cells (MoDC) features. In order to assess whether a differential profile of monocytes may be involved in the generation of these genital MoDCs, we have herein characterized the blood monocyte compartment of Beninese HESNs (HIV-uninfected ≥ 10 years CSWs) and relevant controls (HIV-uninfected 2.5–5 years CSWs herein termed “early HESNs”), HIV-infected CSWs, and low-risk HIV-uninfected women from the general population. Transcriptomic analyses by RNA-Seq of total sorted blood monocytes demonstrate that in comparison to the control groups, HESNs present increased expression levels of FCGR2C, FCAR, ITGAX, ITGAM, CR2, CD68, and CD163 genes, associated with effector functions. Moreover, we found increased expression levels of genes associated with protection/control against SHIV/HIV such as CCL3, CCL4, CCL5, BHLHE40, and TNFSF13, as well as with immune regulation such as IL-10, Ahr, CD83, and the orphan nuclear receptor (NR)4A1, NR4A2, and NR4A3. Through multicolor flow cytometry analyses, we noticed that the frequencies of intermediate and non-classical monocyte populations tended to be elevated in the blood of HESNs, and exhibited increased expression levels of effector CD16, CD11c, CD11b, as well as regulatory HLA-G, IL-10, and IFN-α markers when compared to HIV-uninfected women and/or HIV-infected CSWs. This profile is compatible with that previously reported in the FGT of HESNs, and likely confers an enormous advantage in their resistance to HIV infection.